{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:35:08Z","timestamp":1787578508549,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services","award":["FD005938"],"award-info":[{"award-number":["FD005938"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adequate participation of women, older adults, racial and ethnic subgroups, and other groups, in pivotal trials for cancer therapies is critical for understanding and trusting the safety and efficacy of new medical products across populations. Despite consensus on the importance of representative research and extensive documentation of trial participation barriers, progress has been minimal for most groups, raising the question: What more can be done to enhance participation of underrepresented patient populations in cancer clinical trials, and in turn, improve medical evidence?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a \u201cbright spot\u201d approach to understand what drives successful representation of Black and LatinX patients in cancer clinical trials. We conducted 1-h interviews with \u201cbright spot trial\u201d teams, teams who conducted trials that adequately enrolled Black or LatinX patients relative to disease burden among pivotal trials supporting FDA approval of novel cancer therapeutics between 2012 and 2021, to identify organizational contexts and facilitators associated with success across multiple action levels. Transcripts were analyzed using constant comparative methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen participants from 8 bright spot trial teams described a coherent set of strategies associated with representative enrollment, clustering across five levels: patient and community, clinician, trial and site, sponsor organization, and policy. Key practices included prospective budgeting for mitigating participant expenses; patient- and community co-developed educational programs; navigator use; early clinician engagement and referral training; protocol simplification, decentralization, and broadening of eligibility criteria; expansion into community and satellite hospitals affiliated with NCI Designated Cancer Center trial sites; and sustained, non-transactional community partnerships. At the organizational level, \u201cbright spot trial\u201d teams emphasized the importance of executive leadership commitment, real-time dashboarding on enrollment goals, performance-based incentives, employee training, and minimizing reliance on generic vendor solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sponsors that achieved representative enrollment in oncology trials shared a common operational playbook: reduce patient and site burden, expand access to where care is delivered, widen trial eligibility, invest in trusted relationships, and embed accountability through leadership, data and incentives. Translating these strategies from bright spots into standard practice, supported by clearer regulatory guidance and evaluation, offers a concrete path toward more accessible and generalizable cancer clinical research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16181-1","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:28:19Z","timestamp":1781332099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strategies for enhancing participation of underrepresented patient populations in cancer clinical trials: learning from \u201cbright spots\u201d"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-369X","authenticated-orcid":false,"given":"Jennifer E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakinah C.","family":"Suttiratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"10","key":"16181_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870.","journal-title":"JAMA Oncol"},{"key":"16181_CR2","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720\u20136. https:\/\/doi.org\/10.1001\/jama.291.22.2720.","journal-title":"JAMA"},{"key":"16181_CR3","doi-asserted-by":"crossref","unstructured":"Mendis S,\u00a0AnandS,\u00a0Karasinska JM, et al.\u00a0Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies.\u00a0Oncologist.\u00a02021;26(2):107\u2013114","DOI":"10.1002\/onco.13534"},{"key":"16181_CR4","unstructured":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20792."},{"issue":"6","key":"16181_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamaophthalmol.2021.0855","volume":"139","author":"PH Miskala","year":"2021","unstructured":"Miskala PH, Peter SA. Critical importance of diversity and inclusion in medical product development. JAMA Ophthalmol. 2021;139(6):637\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.0855.","journal-title":"JAMA Ophthalmol"},{"key":"16181_CR6","doi-asserted-by":"publisher","unstructured":"Varma\u00a0T,\u00a0Jones\u00a0CP,\u00a0Oladele\u00a0C, Miller, JE. Diversity in clinical research: public health and social justice imperatives. Journal of Medical Ethics.\u00a0Published Online First:\u00a015 April 2022.\u00a0 https:\/\/doi.org\/10.1136\/medethics-2021-108068.","DOI":"10.1136\/medethics-2021-108068"},{"issue":"6","key":"16181_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jamaoncol.2023.0143","volume":"9","author":"T Varma","year":"2023","unstructured":"Varma T, Gross CP, Miller JE. Clinical trial diversity-will we know it when we see it? JAMA Oncol. 2023;9(6):765\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0143. PMID: 37022678.","journal-title":"JAMA Oncol"},{"key":"16181_CR8","doi-asserted-by":"publisher","unstructured":"Miller JE, Pelletiers W, Gross CP, Mello M, Ramachandran R, Schwartz JL, Suttiratana SC, Varma T, Ross JS. Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012\u20132021: Bright Spot Trials and Trends Over Time. JCO Oncol Pract. 2025:OP2400563. https:\/\/doi.org\/10.1200\/OP-24-00563. Epub ahead of print. PMID: 40493876; PMCID: PMC12360498.","DOI":"10.1200\/OP-24-00563"},{"issue":"18","key":"16181_CR9","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1200\/JCO.23.01030","volume":"42","author":"JM Unger","year":"2024","unstructured":"Unger JM, Shulman LN, Facktor MA, Nelson H, Fleury ME. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. J Clin Oncol. 2024;42(18):2139\u201348. https:\/\/doi.org\/10.1200\/JCO.23.01030. Epub 2024 Apr 2. PMID: 38564681; PMCID: PMC11191051.","journal-title":"J Clin Oncol"},{"key":"16181_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000395","volume":"2","author":"T Varma","year":"2023","unstructured":"Varma T, Mello M, Ross JS, et al. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study. BMJ Med. 2023;2:e000395. https:\/\/doi.org\/10.1136\/bmjmed-2022-000395.","journal-title":"BMJ Med"},{"key":"16181_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5:e191870. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870.","journal-title":"JAMA Oncol"},{"key":"16181_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075547","volume":"14","author":"R Chatters","year":"2024","unstructured":"Chatters R, Dimairo M, Cooper C, et al. Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives. BMJ Open. 2024;14:e075547. https:\/\/doi.org\/10.1136\/bmjopen-2023-075547.","journal-title":"BMJ Open"},{"key":"16181_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","volume":"112","author":"JG Ford","year":"2008","unstructured":"Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228\u201342. https:\/\/doi.org\/10.1002\/cncr.23157.","journal-title":"Cancer"},{"issue":"1","key":"16181_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-000920","volume":"3","author":"J Miller","year":"2024","unstructured":"Miller J, Pelletiers W, Suttiratana S, Mensah MO, Schwartz J, Ramachandran R, et al. Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies. BMJ Med. 2024;3(1):e000920. https:\/\/doi.org\/10.1136\/bmjmed-2024-000920.","journal-title":"BMJ Med"},{"issue":"1","key":"16181_CR15","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.611","volume":"7","author":"E Golbeck","year":"2023","unstructured":"Golbeck E, Jedraszko AM, Hays PT, Herzog KA, D\u2019Aquila RT, Ison MG, et al. Barriers and facilitators to recruitment of underrepresented research participants: perspectives of clinical research coordinators. J Clin Transl Sci. 2023;7(1):e193. https:\/\/doi.org\/10.1017\/cts.2023.611.","journal-title":"J Clin Transl Sci"},{"key":"16181_CR16","unstructured":"https:\/\/dschool.stanford.edu\/k12-lab-network\/positive-deviance-for-educators#:~:text=Positive%20deviance%20(PD)%20is%20a,intractable%20problem%20you%20are%20facing."},{"key":"16181_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-25","volume":"4","author":"EH Bradley","year":"2009","unstructured":"Bradley EH, Curry LA, Ramanadhan S, Rowe L, Nembhard IM, Krumholz HM. Research in action: using positive deviance to improve quality of health care. Implement Sci. 2009;4:25.","journal-title":"Implement Sci"},{"key":"16181_CR18","unstructured":"Singhal, A., & Greiner, K. When the task is accomplished, can we say we did it ourselves?\u00a0A Quest to Eliminate MRSA at the Veterans Health Administration\u2019s Hospitals in Pittsburgh, 2007;1\u201362. http:\/\/tools.patientsafetyinstitute.ca\/Communities\/STOPInfectionsNow\/Shared%20Documents\/Liberating%20Structures%20and%20PD\/Published%20Articles\/VAPHS%20PD%20MRSA%20Story-Singhal-Greiner-Final-June%2018-2007%5B1%5D.pdf."},{"issue":"1","key":"16181_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-45","volume":"14","author":"Y Assefa","year":"2014","unstructured":"Assefa Y, Lynen L, Wouters E, Rasschaert F, Peeters K, Van Damme W. How to improve patient retention in an antiretroviral treatment program in Ethiopia: a mixed-methods study. BMC Health Serv Res. 2014;14(1):45. https:\/\/doi.org\/10.1186\/1472-6963-14-45.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"16181_CR20","volume":"3","author":"TA Klaiman","year":"2014","unstructured":"Klaiman TA, Pantazis A, Bekemeier B. A method for identifying positive deviant local health departments in maternal and child health. Front Public Health Serv Syst Res. 2014;3(2):5.","journal-title":"Front Public Health Serv Syst Res"},{"key":"16181_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1161\/CIRCULATIONAHA.105.590133","volume":"113","author":"EH Bradley","year":"2006","unstructured":"Bradley EH, Curry LA, Webster TR, et al. Achieving rapid door-to-balloon times: how top hospitals improve complex clinical systems. Circulation. 2006;113:1079\u201385.","journal-title":"Circulation"},{"key":"16181_CR22","doi-asserted-by":"crossref","unstructured":"Bradley EH, Roumanis SA, Radford MJ, et al. Achieving door-to-balloon times that meet quality guidelines: how do successful hospitals do it?\u00a0J Am Coll Cardiol.\u00a02005;46:1236","DOI":"10.1016\/j.jacc.2005.07.009"},{"key":"16181_CR23","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1056\/NEJMsa063117","volume":"355","author":"EH Bradley","year":"2006","unstructured":"Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med. 2006;355:2308\u201320.","journal-title":"N Engl J Med"},{"key":"16181_CR24","doi-asserted-by":"crossref","unstructured":"Bradley EH, Holmboe ES, Mattera JA, et al. A qualitative study of increasing beta- blocker use after myocardial infarction: why do some hospitals succeed?\u00a0JAMA.\u00a02001;285:2604","DOI":"10.1001\/jama.285.20.2604"},{"key":"16181_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/00005650-200503000-00011","volume":"43","author":"EH Bradley","year":"2005","unstructured":"Bradley EH, Herrin J, Mattera JA, et al. Quality improvement efforts and hospital performance: rates of beta-blocker prescription after acute myocardial infarction. Med Care. 2005;43:282.","journal-title":"Med Care"},{"key":"16181_CR26","doi-asserted-by":"publisher","unstructured":"Miller J, Pelletiers W,\u00a0Gross C, Mello M,\u00a0Ramachandran R, Schwartz J,\u00a0Suttiratana S,\u00a0Varma T,\u00a0Ross J.\u00a0Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012\u20132021: Bright Spot Trials and Trends Over Time.\u00a0JCO Oncology Practice. 2025;op2400563.\u00a0PMID: 40493876,\u00a0https:\/\/doi.org\/10.1200\/op-24-00563.","DOI":"10.1200\/op-24-00563"},{"key":"16181_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117. https:\/\/doi.org\/10.1186\/1471-2288-13-117.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"16181_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/160940690900800301","volume":"8","author":"AJ Onwuegbuzie","year":"2009","unstructured":"Onwuegbuzie AJ, et al. A qualitative framework for collecting and analyzing data in FG research. Int J Qual Methods. 2009;8(3):1\u201321.","journal-title":"Int J Qual Methods"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16181-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16181-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16181-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:12:58Z","timestamp":1787577178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16181-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16181"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16181-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received an exemption from the Institutional Review Board at the Yale School of Medicine as participants responded to questions about their professional workplaces. All participants provided oral informed consent before completing an electronic survey about their organization and practices and 60-min virtual interviews, grouped by sponsor, on efforts to field their representative clinical trials. A copy of the consent form is available in the Appendix. This study adheres to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were informed that findings from this study would be characterized and disseminated through peer reviewed journal articles.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Schwartz currently receives research support through Yale University from the U.S. National Institutes of Health (NIH), the Greenwall Foundation, and Arnold Ventures. Dr. Ramachandran currently receives research support from Arnold Ventures, The Greenwall Foundation, and Public Citizen for work related to the U.S. Food and Drug Administration (FDA) and previously received research support through Yale University from the Stavros Niarchos Foundation and FDA. She also receives an honorarium through the Reimagining America Fellowship with the Roosevelt Institute as well as personal fees from Debevoise & Plimpton LLP as a consultant outside of submitted work. She previously received consultancy fees from the Johns Hopkins Bloomberg School of Public Health in 2022 for work funded by the Swedish International Development and Cooperation Agency, outside the submitted work. Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the NIH, from the Greenwall Foundation, and from Arnold Ventures. Dr. Miller receives research support through Yale University from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program, Flatiron Health to characterize data sharing practices of NCI-designated cancer centers, BMS to assess the need, value and pathways for access to novel oncology medicines in LMICs, as well as Bioethics International and the Good Pharma Scorecard. Previously she received support from Arnold Ventures through Yale University and served on the bioethics advisory committee for CSL and as a scientific advisor for Galatea Bio.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1009"}}